ReviewProceedings of the Japan Academy. Series B, Physical and biological sciences2018
The causal relationship between epigenetic abnormality and cancer development: in vivo reprogramming and its future application.
Review in Proceedings of the Japan Academy. Series B, Physical and biological sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Advances in epigenetic therapy for esophageal cancer.Clinical epigenetics · 2026Review
- Non-invasive colorectal cancer biomarkers: HAND2 and GPM6A methylation in circulating tumour DNA.Cancer cell international · 2025Article
- In Vivo Reprogramming Highlights Epigenetic Regulation That Shapes Cancer Hallmarks.Cancer science · 2025Review
- Research ofRegenerative therapy · 2025Review
- Is Cancer Metabolism an Atavism?Cancers · 2024Review
- Epigenetic regulation in lung cancer.MedComm · 2023Review
- Dedifferentiation andMolecular medicine reports · 2022Review
- Correlations between histological characterizations and methylation statuses of tumour suppressor genes in Wilms' tumours.International journal of experimental pathology · 2022Article
- LncRNAInternational journal of molecular sciences · 2021Review
- Epidrugs: targeting epigenetic marks in cancer treatment.Epigenetics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is increasing evidence that cancer cells acquire epigenetic abnormalities as well as genetic mutations during cancer initiation, maintenance, and progression. However, the role of epigenetic regulation in cancer development, especially at the organismal level, remains to be elucidated. Here, we describe the causative role of epigenetic abnormalities in cancer, referring to our in vivo studies using induced pluripotent stem cell technology. We first summarize epigenetic reorganization during cellular reprogramming and introduce our in vivo reprogramming system for investigating the impact of dedifferentiation-driven epigenetic disruption in cancer development. Accordingly, we propose that particular types of cancer, in which causative mutations are not often detectable, such as pediatric cancers like Wilms' tumor, may develop mainly through alterations in epigenetic regulation triggered by dedifferentiation. Finally, we discuss issues that still remain to be resolved, and propose possible future applications of in vivo reprogramming to study cancer and other biological phenomena including organismal aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.